Key words: longitudinal; nonsmoking; pulmonary function; rheumatoid arthritis
|
|
- Annis Thomas
- 6 years ago
- Views:
Transcription
1 A Longitudinal Study of Lung Function in Nonsmoking Patients With Rheumatoid Arthritis* Jonathan P. Fuld, MBChB; Martin K. Johnson, MBChB; Mark M. Cotton, MBBS; Roger Carter, PhD; Simon W. Watkin, MBChB; Hilary A. Capell, MD; and Robin D. Stevenson, MD Study objectives: Patients with rheumatoid arthritis (RA) have a high prevalence of pulmonary function test (PFT) abnormality, but the long-term significance of this is unknown. We performed a longitudinal study of pulmonary function in asymptomatic, nonsmoking patients with active RA requiring disease-modifying drugs. We looked for temporal change in lung function and characteristics that would predict subsequent development of PFT abnormality or respiratory symptoms. Methods: In 1990, 52 patients (44 women; age range, 29 to 78 years; median, 56 years) underwent clinical assessment (drug history, RA severity, immunologic, and inflammatory markers) and PFTs (spirometry, body plethysmography, gas transfer). PFT results were expressed as standardized residuals (SRs). Thirty-eight patients were reassessed in A self-administered questionnaire was used to identify respiratory symptoms. Results: The prevalence of pulmonary function abnormality was higher than expected compared with a reference population, but there was no significant increase in number over 10 years (8.7% in 1990 and 8.8% in 2000). When assessed by group means and compared with reference values, reduced diffusing capacity of the lung for carbon monoxide (DLCO) and increased ratio of residual volume (RV) to total lung capacity (TLC) [RV/TLC] were the only abnormalities to develop over the study period (mean DLCO in 2000, 0.47 SR; 95% confidence interval [CI], 0.91 to 0.01; RV/TLC, 0.49 SR; 95% CI, 0.13 to 0.84). However, rates of change of pulmonary function variables were not significantly different from zero. Logistic regression did not identify any meaningful relationship between disease characteristics and PFT abnormality. Conclusions: Asymptomatic patients with RA have a higher prevalence of PFT abnormality than expected, but these do not increase in number over time. We did not identify any patient or disease-specific characteristic that could predict the development of respiratory disease in patients with RA. Analysis using percentage of predicted values, rather than SRs, is misleading as it exaggerates the extent of abnormality present. Abnormal lung function is a common and probably benign finding in nonsmoking, asymptomatic patients with RA. (CHEST 2003; 124: ) Key words: longitudinal; nonsmoking; pulmonary function; rheumatoid arthritis Abbreviations: ANF antinuclear factor; CI confidence interval; CRP C-reactive protein; Dlco diffusing capacity of the lung for carbon monoxide; DMARD disease-modifying antirheumatoid drug; ESR erythrocyte sedimentation rate; FEF midexpiratory flow; HRCT high-resolution CT; KCO transfer coefficient for carbon monoxide; PFT pulmonary function test; RA rheumatoid arthritis; RF rheumatoid factor; RV residual volume; sgaw specific airways conductance; SR standardized residual; TLC total lung capacity; VC vital capacity Rheumatoid arthritis (RA) is a common multisystem disorder of unknown etiology affecting approximately 1% of the population. 1 Cross-sectional *From the Department of Respiratory Medicine (Drs. Fuld, Johnson, Cotton, Carter, and Stevenson), Glasgow Royal Infirmary, Glasgow; Department of Respiratory Medicine (Dr. Watkin), Norfolk and Norwich Hospital, Norwich; and Centre for Rheumatic Diseases (Dr. Capell), Glasgow Royal Infirmary, Glasgow, UK. Manuscript received October 30, 2002; revision accepted May 14, surveys of lung function in RA are common and have demonstrated a high prevalence of abnormality characteristic of interstitial and both large and small airway disease. 2 5 More recently, high-resolution CT Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( permissions@chestnet.org). Correspondence to: Jonathan P. Fuld, MBChB, Department of Respiratory Medicine, Ground floor, Queen Elizabeth Building, Glasgow Royal Infirmary, G31 2ER, Glasgow, UK; j.fuld@bio.gla.ac.uk 1224 Clinical Investigations
2 (HRCT) has confirmed the high prevalence of parenchymal and airway disease, often in asymptomatic patients and sometimes in the absence of pulmonary function or radiographic abnormality. 6,7 The outcome of such patients with subclinical pulmonary involvement is unknown. Previous longitudinal studies of pulmonary function in patients with RA have not suggested a consistent pattern of change. Beyeler et al 8 showed a decrease in FEV 1, whereas Linstow et al 9 described an increase in diffusing capacity of the lung for carbon monoxide (Dlco), and Chakravarty and Webley 10 reported reversible pulmonary function changes, suggestive of interstitial disease, after introduction of gold. All these studies have included smokers, and Beyeler et al 8 and Chakravarty and Webley 10 attempted to assess the impact of drug therapy on pulmonary function. The purpose of this study was to ascertain the prevalence of pulmonary function test (PFT) abnormalities in a population of nonsmoking patients with RA and no respiratory symptoms. We wished to determine how these changed over a 10-year period and identify factors that might predict the onset of symptoms or abnormality of lung function. Recruitment Materials and Methods In 1990, we recruited patients from the RA second-line medication clinic at the Centre for Rheumatic Diseases at Glasgow Royal Infirmary. All patients had RA diagnosed by a consultant rheumatologist, according to American College of Rheumatology criteria, 11 and were receiving one or more diseasemodifying antirheumatoid drugs (DMARDs). Inclusion criteria were lifelong nonsmoking, no documented or recalled evidence of lung disease, and absence of respiratory symptoms on general inquiry at initial consultation. Informed consent was obtained from all patients, and the local Research Ethics Committee approved the study. Clinical Evaluation In 1990, we recorded rheumatoid factor (RF) and antinuclear factor (ANF) titers, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), articular disease status (Ritchie articular index), duration of morning stiffness, and history of DMARD use. 12 ESR was measured by a Starsed assay (Mechatronics; R&R Hoorn, Holland). RF titer was determined by nephelometry, with a titer of 22 IU/mL indicating seropositivity. ANF titer was determined by indirect immunofluorescence using rat liver substrate. CRP was determined by photometric analysis, with a titer of 6 mmol/l indicating normality. All patients underwent comprehensive PFTs. In 2000, the patients were invited to attend for repeat assessment. They underwent the same PFTs and also completed a modified form of a self-administered respiratory symptom questionnaire (American Thoracic Society Division of Lung Diseases 78-A adult symptom questionnaire). 13 Questions concerning passive smoking exposure were added, and the language was altered in some places to British from American English. The expected prevalence of symptoms was obtained from the third National Health and Nutrition Examination Survey. 14 Pulmonary Function Spirometry, flow-volume loops, and lung volumes were measured using the Morgan Medical Autobox (Morgan Medical; Kent, UK) in 1990 and the V6200 Autobox (SensorMedics Corporation; Yorba Linda, CA) in The variables measured were vital capacity (VC), FEV 1, mid-expiratory flow (FEF ), residual volume (RV), total lung capacity (TLC), specific airways resistance, and specific airways conductance (sgaw). Dlco was measured with the single-breath technique using the Transflow System (Model 540; Morgan Medical). These values were corrected for hemoglobin concentration. Tests were performed according to the British Thoracic Society/Association of Respiratory Technology and Physiology guidelines. 15 The same investigator performed the tests in 1990 and Results of at least three satisfactory maneuvers were analyzed, and the reported values were the highest value for FEV 1 and VC and the mean of the three results for each of the remaining indexes. We used the regression equations for normal values derived from the European coal and mineworker s database, 16 which use height, age, and sex as independent variables. Excluding one subject, the median difference (interquartile range) in height over the study period was 1cm( 3 to 1 cm). This is commensurate with age-related change. One subject was severely affected by spinal deformity over the study period, losing 17 cm in height; in this case, arm span was used. Values were defined as abnormal if greater than two standardized residuals (SRs) from the predicted result. Statistical Analysis Group data are shown as mean SD unless otherwise specified. Pulmonary function data have been given as mean absolute values and SRs. The latter are calculated from the following: SR (observed value predicted value)/rsd where RSD is the residual SD taken from the regression equation used to derive the predicted value. 15 Statistical significance was assessed using the one-sample t test, the 2 test, and differences between proportions using the binomial distribution. Binary logistic regression was used to identify predictors of respiratory complications. All statistical analysis was performed with Statview software (SAS Institute; Cary, NC), except for binary logistic regression where Minitab 13 (Minitab; State College, PA) was used. Values of p 0.05 were considered significant. Results We studied 52 patients (44 women; age range, 29 to 78 years; median, 56 years). Thirty-eight patients were seropositive, and all were receiving DMARD therapy with a median lifetime use of two agents (range, one to four agents). The DMARDs used and the number of patients prescribed them are as follows: IM gold (n 25), sulfasalazine (n 22), penicillamine (n 11), hydroxychloroquine (n 8), methotrexate (n 4), and azathioprine (n 3). Only three patients had been solely administered CHEST / 124 / 4/ OCTOBER,
3 hydroxychloroquine, indicating that we had a very small number of patients with mild rheumatoid disease. Patient characteristics at study entry are shown in Table 1. By 2000, 9 patients of the original cohort had died and 43 patients were invited for reassessment. Two had died from respiratory disease (pulmonary fibrosis, lung cancer/tuberculosis), and the remaining seven patients died from extrapulmonary malignancy (n 4), ischemic heart disease (n 1), renal failure (n 1), and general debility (n 1). Figure 1 summarizes patient follow-up. Cross-Sectional Results Table 2 shows the group mean PFT results for all patients in Both FEV 1 /VC and FEF were significantly lower than predicted. VC was significantly higher than predicted, but this was not considered to be of physical significance. In 1990 for the subset of patients with repeat values only, FEF was significantly reduced ( 1.22 SR; range, 1.68 to 0.76; n 13; p ). Table 3 shows the follow-up PFT results. FEF has remained low, but now RV/TLC was significantly increased and Dlco reduced. Only 31 of our group had Dlco measurements performed in both 1990 and Figure 2 shows the distribution of Dlco and RV/ TLC in both 1990 and Mean measurements of sgaw for the 50 patients from 1990, the retested 38 patients in the subgroup, and the 2000 repeats were kpa/s, kpa/s, and kpa/s, respectively (normal value, 1.1 kpa/s). Mean values of specific airways resistance for all the 1990 patients, the retested subgroup, and the 2000 repeats were kpa/s/l, kpa/s/l, and kpa/s/l (normal value, 0.2 kpa/s/l). Longitudinal Results To enable comparison of longitudinal changes between the various pulmonary function parameters, Table 1 Baseline Characteristics in 1990 Characteristics Median (Range) Age, yr 56 (29 78) Disease duration, yr 14 ( ) Lifetime DMARD use, No. of agents 2 (1 4) Morning stiffness, min 30 (0 720) Ritchie articular index 2 (0 30) Pain score 32 (0 75) RF (38 positive) 1/256 (1/16 1/1,024) ANA (30 positive) 1/256 (1/32 1/2,048) ESR, mm/h 40 (4 137) CRP, mmol/l 16 (5 235) Figure 1. Patient follow-up. we calculated the difference (in SRs) between measured and predicted values for each subject with repeat values. We then expressed these as a rate of change by dividing the change in difference between the two sets of PFTs by the time interval in years. None of the rates of change of SR was significant. The decline in Dlco was a trend only, with a p value of 0.1. Although we could demonstrate an abnormality when the longitudinal results were compared with a reference population, we could not demonstrate a difference between the results from the two time points. Mean SR values are displayed in Figure 3. The percentage of PFTs that lay outside the normal range in 1990 was higher than expected when compared with a reference population (8.7% vs 5%, p 0.003). In 2000, the incidence of abnormality remained higher than expected (8.8% vs 5%, p 0.003), with no significant change over the 10 years. To examine the changes in type of PFT abnormality over time, we classified patients with abnormal PFTs as having an obstructive, restrictive, or mixed pattern (Table 4). There were no significant differences in the patterns of abnormality or total numbers of patients with abnormality between 1990 and 2000 (p 0.2). Twenty-seven percent of our population in 1990 and 2000 had PFT abnormalities that together could be classified as suggesting a disease pattern. Symptom Results Forty patients in 2000 completed the respiratory symptom questionnaire either when reassessed (n 34) or by telephone (n 6). Thirty-five percent of this cohort had acquired respiratory symptoms. Breathlessness was most common (25%), followed by cough (16%), sputum production (12.5%), and wheeze (7.5%). The expected prevalence figures of 1226 Clinical Investigations
4 Table 2 Results for All Study Patients in 1990* Tests No. Mean (95% CI) Standardized Residuals p Value FEV 1,L (1.16 to 3.56) 0.06 ( 0.42 to 0.30) 0.73 FEV 1 /VC, % (60.6 to 92.2) 0.31 ( 0.6 to 0.01) VC, L (1.72 to 4.56) 0.30 (0.14 to 0.56) NPS RV, L (0.89 to 2.77) ( 0.25 to 0.44) 0.58 TLC, L (3.11 to 6.87) 0.18 ( 0.16 to 0.52) 0.30 RV/TLC, % (19.4 to 48.6) 0.25 ( 0.04 to 0.55) 0.09 FEF 25 75, L/s (0.5 to 3.62) 1.15 ( 1.5 to 0.83) Dlco, mmol/mm Hg/min (9.72 to 32.0) 0.07 ( 0.43 to 0.30) 0.71 *NPS no physical significance. Values adjusted for hemoglobin. these symptoms in lifelong age-matched nonsmokers are 20.4%, 6.1%, 5%, and 7.7%, respectively. The presence of symptoms in 2000 was not associated with abnormal lung function in either 1990 or 2000 when assessed by binary logistic regression. Regression Analysis Binary logistic regression was used to try to predict membership of the following patient groups: (1) those with PFT abnormalities in 1990, (2) those with PFT abnormalities in 2000, (3) those who acquired respiratory symptoms, (4) those who did not attend for repeat tests, and (5) those who died. The variables used either singly or in combination in the prediction model were sex, age, passive smoking exposure, ESR, CRP, disease duration, pain score, articular index, RF, ANF, DMARD use, and PFT abnormality in Very few positive associations were found. The only factors predicting abnormal lung function in 2000 were initial abnormality in 1990 (p 0.008) and shorter disease duration (p 0.04). A worse outcome (death or failure to reattend) was associated with a higher pain score (p 0.03) and negatively with sulfasalazine use (p 0.04). Discussion There have been a considerable number of crosssectional studies looking at the prevalence of pulmonary abnormalities in patients with RA who were not known to have lung involvement. The older studies 4,5,17 24 used PFTs to detect the abnormalities, whereas in more recent times this has been combined with HRCT of the thorax 6,7,25 28 ; all studies concur in that a high prevalence of abnormality (35 to 65%) can be found. By contrast, 27% of our population had pulmonary function abnormalities that may represent patterns of disease in both 1990 and However, there is significant heterogeneity between study results in terms of the type of abnormality detected. Whereas in some cases, the predominant defect was volume restriction with impaired gas transfer, 18,20,26,29 in others airway obstruction, both large and small, predominated. 4,17,21,23,24 In the studies 6,25,30,31 with HRCT, bronchiectasis was sometimes the most common lesion. This heterogeneity could reflect differences in study design. Clearly, the diagnostic modality used (radiology or physiology) will have a large impact on the range of lesions detected. Few studies selected a cohort of nonsmoking patients, 22,24,28,32 and in all cases a proportion of the subjects had preexisting respiratory symptoms. All patients had RA, but some studies applied further inclusion criteria such as disease activity or DMARD use. 8,10,33,34 In defining the presence of PFT abnormality, studies 6,20,22 have applied different criteria, some using percentage of predicted ranges and others using confidence intervals (CIs) derived from SRs. 3,8 Table 3 Results in 2000 for Subset Who Returned for Repeat Assessment* Tests No. Mean (95% CI) SRs Mean (95% CI) p Value FEV 1,L (0.91 to 3.46) ( 0.36 to 0.39) 0.93 FEV 1 /VC, % (60.0 to 92.1) 0.17 ( 0.54 to 0.2) 0.36 VC, L (1.38 to 4.45) 0.47 (0.11 to 0.84) NPS RV, L (1.10 to 2.80) ( 0.24 to 0.55) 0.43 TLC, L (3.02 to 6.63) ( 0.42 to 0.42) 1.0 RV/TLC, % (30.1 to 62.1) 0.49 (0.13 to 0.84) FEF 25 75, L/s (0.26 to 4.39) 1.06 ( 1.48 to 0.65) Dlco, mmol/mm Hg/min (6.46 to 29.5) 0.47 ( 0.91 to 0.01) *See Table 2 for expansion of abbreviation. Values adjusted for hemoglobin. CHEST / 124 / 4/ OCTOBER,
5 Figure 2. Distribution of Dlco and RV/TLC results in 1990 and Error bars represent mean 2 SD. Of the two, the use of SRs is more methodologically sound. 35 There are a number of drawbacks to an analysis based on percentage of predicted values. They overestimate the significance of lung function variation in smaller and older subjects, which makes the combination of group results of uncertain validity and can lead to the description of significant abnormality where none exists. Lung volumes have a natural decline with age, but the spread of values remains unaltered; therefore, percentage of predicted values would show an erroneous change over time, whereas SRs avoid this problem. This is because the denominator is becoming smaller while the absolute difference between the actual and the Figure 3. Longitudinal change in PFT variables between 1990 and 2000 for the subset that reattended. Values are mean SRs. *Significantly different from zero (p 0.05), but there are no significant changes between the 1990 and 2000 results Clinical Investigations
6 Table 4 Incidence of Patterns of Abnormality Patterns* Obstructive 7/41 5/41 Restrictive 2/41 3/41 Mixed 2/41 3/41 Any abnormality 11/41 11/41 *Obstructive low FEV/VC or low sgaw or low FEF or high RV/TLC; restrictive low VC or low TLC or low Dlco; any abnormality obstructive or restrictive or mixed. predicted value is unchanged. The reporting of SRs also allows direct comparison of the degree of abnormality between PFT variables that have different units and SDs. To demonstrate the effect of using percentage of predicted values rather than SRs, the group mean values from Table 2 are shown again in Table 5, but this time using percentage of predicted. A onesample analysis for significance assuming a mean value of 100% has been performed. As can be seen, many more of the PFT variables appear abnormal, which is erroneous. There are fewer studies 8 10,33,34 that have looked at longitudinal change in pulmonary function in patients with RA. Again, these are of heterogeneous design with conflicting results. The study 9 with the longest follow-up assessed pulmonary function over an 8-year period in 63 patients with RA. At entry, all the patients had reduced Dlco. They found that Dlco and transfer coefficient for carbon monoxide (KCO) improved but VC decreased. This unexpected gas transfer finding could represent regression toward the mean given the way in which the subjects were selected. The most similar study 8 to ours looked at 96 patients receiving methotrexate, which reported small but significant reductions in FEV 1 /FVC and Dlco and increase in alveolararterial oxygen pressure difference over the follow-up period. Three further studies 10,33,34 assessed pulmonary function following the introduction of a DMARD. In the article by Chakravarty and Web- Table 5 Results for All Study Patients in 1990 Tests No. Percentage Predicted Mean (95% CI) p Value FEV (90 101) 0.08 FEV 1 /VC (97 105) 0.8 VC (90 99) 0.01 RV ( ) TLC ( ) 0.02 RV/TLC ( ) 0.08 FEF (70 90) Dlco* ( ) *Values adjusted for hemoglobin. ley, 10 patients were randomly assigned to gold, penicillamine, or azathioprine. A significant proportion receiving gold and penicillamine acquired a restrictive-type defect (reduction in VC and KCO) within 2 years that improved in the case of gold after withdrawal of the DMARD. In the articles by Cottin et al 33 and Dayton et al 34, 124 subjects and 31 subjects, respectively, were commenced on methotrexate. 33,34 In the former case, statistically significant but subclinical reductions in VC and KCO were seen at 2 years, but the latter study failed to replicate this finding. None of these studies were able to identify disease factors that would predict accelerated deterioration of PFT results. In our study, we have tried to address some of the limitations of the earlier research. We enrolled a well-defined population from which results could be generalized. This was done by selecting patients with significant rheumatoid disease activity (defined by established use of DMARD) and excluding any patients with preexisting respiratory symptoms. Our subjects were assessed after a long time interval (10 years) to enhance the sensitivity of the study in detection of temporal trends. We included only lifelong nonsmokers to eliminate this as a confounding variable. All measurements were expressed as SRs and were independent of the influence of age, height, sex, and time. The cross-sectional results in Table 2 extend the findings of earlier studies. A nonsmoking RA population with no respiratory symptoms shows minor PFT abnormalities when compared with reference values, namely a reduced FEV 1 /FVC ratio as mentioned earlier. Although FEF was also decreased, we hesitate to attach any significance to this, as results were only available for a small subset of our patients. In the 41 patients who were reassessed, the prevalence of abnormal PFTs was higher than expected but did not increase. Despite this, at reassessment mean Dlco had become significantly reduced and mean RV/TLC significantly elevated when compared with reference values. (Note, however, that this did not represent a significant difference from the initial results). Such changes in gas transfer have been found by others, 10,33 and could suggest development of early parenchymal lung abnormality. By contrast, an increase in RV/TLC ratio suggests worsening of air trapping and airways obstruction. As with preceding studies, 8,9 we have attempted to use patient characteristics to predict who would acquire respiratory complications. We were only able to define preexisting abnormality and shorter disease duration as factors that may predict those patients who will have abnormal PFT results. The former is to be expected and reassures us that the abnormalities found were permanent and not measurement CHEST / 124 / 4/ OCTOBER,
7 errors. As regards disease duration, this finding perhaps suggests that if PFT abnormalities are going to develop, then this will occur early in the course of the disease. Although one of our subjects with initially abnormal results died from progressive lung disease in the intervening period, in general abnormal initial PFT results did not predict a bad outcome. We are not able to explain the negative association found between sulfasalazine use and poor outcome, as the group treated with this agent were no different from the other subjects with respect to RA characteristics. A significant proportion (35%) of our patients acquired respiratory symptoms by the end of the 10-year period, which was in excess of that expected for healthy, lifelong nonsmokers, and is in keeping with the higher prevalence of PFT abnormality in the study cohort. This figure is likely to be inflated as initial symptom evaluation was by informal questioning, whereas at reassessment we used a more sensitive tool. However, neither symptoms nor passive smoking exposure were associated with the development of pulmonary function abnormality or with a poor outcome. Conclusions We have demonstrated that, within a population of patients with RA selected as lifelong nonsmokers with no respiratory symptoms, the prevalence of pulmonary function abnormality is higher than expected when compared with a reference population, but did not increase over 10 years. Assessed by group means and SRs, both Dlco and RV/TLC became significantly abnormal in 2000 when compared with reference values. However, rates of change of pulmonary function variables were not significantly different from zero, and no particular trend emerged when patients were classified as having an obstructive, restrictive, or mixed picture. Neither disease characteristics nor development of respiratory symptoms were associated with abnormal lung function. Analysis using percentage of predicted values, rather than SRs, is misleading, as it exaggerates the extent of abnormality present. Abnormal lung function is a common and probably benign finding in nonsmoking, asymptomatic patients with RA. References 1 Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am 1990; 16: Frank ST, Weg JG, Harkleroad LE, et al. Pulmonary dysfunction in rheumatoid disease. Chest 1973; 63: Banks J, Banks C, Cheong B, et al. An epidemiological and clinical investigation of pulmonary function and respiratory symptoms in patients with rheumatoid arthritis. Q J Med 1992; 85: Collins RL, Turner RA, Johnson AM, et al. Obstructive pulmonary disease in rheumatoid arthritis. Arthritis Rheum 1976; 19: Geddes DM, Webley M, Emerson PA. Airways obstruction in rheumatoid arthritis. Ann Rheum Dis 1979; 38: Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998; 157: Demir R, Bodur H, Tokoglu F, et al. High resolution computed tomography of the lungs in patients with rheumatoid arthritis. Rheumatol Int 1999; 19: Beyeler C, Jordi B, Gerber NJ, et al. Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1996; 35: Linstow M, Ulrik CS, Kriegbaum NJ, et al. An 8-year follow-up study of pulmonary function in patients with rheumatoid arthritis. Rheumatol Int 1994; 14: Chakravarty K, Webley M. A longitudinal study of pulmonary function in patients with rheumatoid arthritis treated with gold and D-penicillamine. Br J Rheumatol 1992; 31: Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; 37: Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978; 118: National Center for Health Statistics. Third National Health and Nutrition Examination Survey, , NHANES III laboratory data file. Atlanta, GA: Centers for Disease Control and Prevention, Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Respir Med 1994; 88: Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows: Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal; official statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: Vergnenegre A, Pugnere N, Antonini MT, et al. Airway obstruction and rheumatoid arthritis. Eur Respir J 1997; 10: Oxholm P, Madsen EB, Manthorpe R, et al. Pulmonary function in patients with rheumatoid arthritis. Scand J Rheumatol 1982; 11: Morrison SC, Mody GM, Benatar SR, et al. The lungs in rheumatoid arthritis: a clinical, radiographic and pulmonary function study. S Afr Med J 1996; 86: Hyland RH, Gordon DA, Broder I, et al. A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis. J Rheumatol 1983; 10: Radoux V, Menard HA, Begin R, et al. Airways disease in rheumatoid arthritis patients: one element of a general exocrine dysfunction. Arthritis Rheum 1987; 30: Andonopoulos AP, Constantopoulos SH, Drosos AA, et al. Pulmonary function of nonsmoking patients with rheumatoid arthritis in the presence and absence of secondary Sjogren s syndrome, a controlled study. Respiration 1988; 53: Hassan WU, Keaney NP, Holland CD, et al. Bronchial reactivity and airflow obstruction in rheumatoid arthritis. Ann Rheum Dis 1994; 53: Clinical Investigations
8 24 Lee JH, Suh GY, Lee KY, et al. Small airway disease in rheumatoid arthritis. Korean J Intern Med 1992; 7: Despaux J, Manzoni P, Toussirot E, et al. Prospective study of the prevalence of bronchiectasis in rheumatoid arthritis using high-resolution computed tomography. Rev Rhum Engl Ed 1998; 65: Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156: Muller-Leisse C, Bussmann A, Meyer O, et al. Pulmonary manifestations in rheumatoid arthritis: high-resolution computed tomography in correlation with the skeletal changes and the laboratory chemical changes [in German]. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996; 165: Hassan WU, Keaney NP, Holland CD, et al. High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54: Andonopoulos AP, Drosos AA, Skopouli FN, et al. Secondary Sjogren s syndrome in rheumatoid arthritis. J Rheumatol 1987; 14: McDonagh J, Greaves M, Wright AR, et al. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatol 1994; 33: Remy-Jardin M, Remy J, Cortet B, et al. Lung changes in rheumatoid arthritis: CT findings. Radiology 1994; 193: Begin R, Masse S, Cantin A, et al. Airway disease in a subset of nonsmoking rheumatoid patients: characterization of the disease and evidence for an autoimmune pathogenesis. Am J Med 1982; 72: Cottin V, Tebib J, Massonnet B, et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996; 109: Dayton CS, Schwartz DA, Sprince NL, et al. Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Am J Respir Crit Care Med 1995; 151: Miller MR, Pincock AC. Predicted values: how should we use them? Thorax 1998; 43: CHEST / 124 / 4/ OCTOBER,
Pulmonary involvement contributes significantly to morbidity
Pulmonary Functions Testing in Patients with Rheumatoid Arthritis Lone S. Avnon MD 1, Fauaz Manzur MD 2, Arkadi Bolotin PhD 3, Dov Heimer MD 1, Daniel Flusser MD 2, Dan Buskila MD 2, Shaul Sukenik MD 2
More informationChapter. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension
Chapter 7 Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension P. Trip B. Girerd H.J. Bogaard F.S. de Man A. Boonstra G. Garcia M. Humbert D. Montani A. Vonk Noordegraaf Eur Respir
More informationDifference Between The Slow Vital Capacity And Forced Vital Capacity: Predictor Of Hyperinflation In Patients With Airflow Obstruction
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 4 Number 2 Difference Between The Slow Vital Capacity And Forced Vital Capacity: Predictor Of Hyperinflation In Patients With Airflow Obstruction
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79. ISSN (e)-37-176x ISSN (p) - DOI: https://dx.doi.org/.183/jmscr/v6i1.18 A Study on Pulmonary Function Test in Patients
More informationPulmonary Function Testing
In the Clinic Pulmonary Function Testing Hawa Edriss MD, Gilbert Berdine MD The term PFT encompasses three different measures of lung function: spirometry, lung volumes, and diffusion capacity. In this
More informationWhat do pulmonary function tests tell you?
Pulmonary Function Testing Michael Wert, MD Assistant Professor Clinical Department of Internal Medicine Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical
More informationPFT Interpretation and Reference Values
PFT Interpretation and Reference Values September 21, 2018 Eric Wong Objectives Understand the components of PFT Interpretation of PFT Clinical Patterns How to choose Reference Values 3 Components Spirometry
More informationSGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life
SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective
More informationPREDICTION EQUATIONS FOR LUNG FUNCTION IN HEALTHY, LIFE TIME NEVER-SMOKING MALAYSIAN POPULATION
Prediction Equations for Lung Function in Healthy, Non-smoking Malaysian Population PREDICTION EQUATIONS FOR LUNG FUNCTION IN HEALTHY, LIFE TIME NEVER-SMOKING MALAYSIAN POPULATION Justin Gnanou, Brinnell
More informationAirway obstruction and rheumatoid arthritis
Eur Respir J 1997; 10: 1072 1078 DOI: 10.1183/09031936.97.10051072 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Airway obstruction and
More informationClinical Study Bronchial Responsiveness in Patients with Restrictive Spirometry
BioMed Research International Volume 2013, Article ID 498205, 5 pages http://dx.doi.org/10.1155/2013/498205 Clinical Study Bronchial Responsiveness in Patients with Restrictive Spirometry Jean I. Keddissi,
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationPULMONARY FUNCTION TESTING. Purposes of Pulmonary Tests. General Categories of Lung Diseases. Types of PF Tests
PULMONARY FUNCTION TESTING Wyka Chapter 13 Various AARC Clinical Practice Guidelines Purposes of Pulmonary Tests Is lung disease present? If so, is it reversible? If so, what type of lung disease is present?
More informationLung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects
Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects Use of GOLD and ATS Criteria Connie Paladenech, RRT, RCP, FAARC Benefits and Limitations of Pulmonary Function Testing Benefits
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationClinical pulmonary physiology. How to report lung function tests
Clinical pulmonary physiology or How to report lung function tests Lung function testing A brief history Why measure? What can you measure? Interpretation/ reporting Examples and case histories Exercise
More informationC.S. HAWORTH 1, A. WANNER 2, J. FROEHLICH 3, T. O'NEAL 3, A. DAVIS 4, I. GONDA 3, A. O'DONNELL 5
Inhaled Liposomal Ciprofloxacin in Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa: Results From Two Parallel Phase III Trials (ORBIT-3 and -4) C.S. HAWORTH 1, A. WANNER
More informationBasic approach to PFT interpretation. Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic
Basic approach to PFT interpretation Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic Disclosures Received honorarium from Astra Zeneca for education presentations Tasked Asked
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationUSEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS
USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS Brestas P., Vergadis V., Emmanouil E., Malagari K. 2 nd Dept of Radiology, University of Athens, Greece ABSTRACT
More informationCIRCULAR INSTRUCTION REGARDING ESTABLISHMENT OF IMPAIRMENT DUE TO OCCUPATIONAL LUNG DISEASE FOR THE PURPOSES OF AWARDING PERMANENT DISABLEMENT
Circular Instruction 195 CIRCULAR INSTRUCTION REGARDING ESTABLISHMENT OF IMPAIRMENT DUE TO OCCUPATIONAL LUNG DISEASE FOR THE PURPOSES OF AWARDING PERMANENT DISABLEMENT COMPENSATION FOR OCCUPATIONAL INJURIES
More informationInterpreting pulmonary function tests: Recognize the pattern, and the diagnosis will follow
REVIEW FEYROUZ AL-ASHKAR, MD Department of General Internal Medicine, The Cleveland Clinic REENA MEHRA, MD Department of Pulmonary and Critical Care Medicine, University Hospitals, Cleveland PETER J. MAZZONE,
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationSTUDY OF PULMONARY ARTERIAL HYPERTENSION IN RESPIRATORY DISORDERS
STUDY OF PULMONARY ARTERIAL HYPERTENSION IN RESPIRATORY DISORDERS *Hegde R.R., Bharambe R.S., Phadtare J.M. and Ramraje N.N. Department of Pulmonary Medicine, Grant Government Medical College, Mumbai-8
More informationPulmonary involvement in ankylosing spondylitis
Annals of the Rheumatic Diseases 1986, 45, 736-74 Pulmonary involvement in ankylosing spondylitis NILS FELTELIUS,1 HANS HEDENSTROM,2 GUNNAR HILLERDAL,3 AND ROGER HALLGREN' From the Departments of 'Internal
More informationMaximal expiratory flow rates (MEFR) measured. Maximal Inspiratory Flow Rates in Patients With COPD*
Maximal Inspiratory Flow Rates in Patients With COPD* Dan Stănescu, MD, PhD; Claude Veriter, MA; and Karel P. Van de Woestijne, MD, PhD Objectives: To assess the relevance of maximal inspiratory flow rates
More informationContent Indica c tion Lung v olumes e & Lung Indica c tions i n c paci c ties
Spirometry Content Indication Indications in occupational medicine Contraindications Confounding factors Complications Type of spirometer Lung volumes & Lung capacities Spirometric values Hygiene &
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationPulmonary Function Testing The Basics of Interpretation
Pulmonary Function Testing The Basics of Interpretation Jennifer Hale, M.D. Valley Baptist Family Practice Residency Objectives Identify the components of PFTs Describe the indications Develop a stepwise
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationTreatment of rapidly progressive rheumatoid
British Journal of Industrial Medicine, 1973, 30, 396-401 Treatment of rapidly progressive rheumatoid pneu moconiosis DEWI DAVI ES Ransom Hospital, Mansfield, Nottinghamshire Davies, D. (1973). British
More informationLung function abnormalities and decline of spirometry in scleroderma: an overrated danger?
Postgrad Med J (1991) 67, 632-637 i) The Fellowship of Postgraduate Medicine, 1991 Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger? M.J. Abramson, A.J. Barnett',
More informationTo assess the pulmonary impairment in treated pulmonary tuberculosis patients using spirometry
Original Research Article To assess the pulmonary impairment in treated pulmonary tuberculosis patients using spirometry Dhipu Mathew 1, Kirthana G 2, Krishnapriya R 1, Srinivasan R 3 1 Assistant Professor,
More informationUnderstanding the Basics of Spirometry It s not just about yelling blow
Understanding the Basics of Spirometry It s not just about yelling blow Carl D. Mottram, RRT RPFT FAARC Technical Director - Pulmonary Function Labs and Rehabilitation Associate Professor of Medicine -
More informationCoexistence of confirmed obstruction in spirometry and restriction in body plethysmography, e.g.: COPD + pulmonary fibrosis
Volumes: IRV inspiratory reserve volume Vt tidal volume ERV expiratory reserve volume RV residual volume Marcin Grabicki Department of Pulmonology, Allergology and Respiratory Oncology Poznań University
More informationPulmonary Function Testing. Ramez Sunna MD, FCCP
Pulmonary Function Testing Ramez Sunna MD, FCCP Lecture Overview General Introduction Indications and Uses Technical aspects Interpretation Patterns of Abnormalities When to perform a PFT 1. Evaluation
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter
More informationNOTICE OF SUBSTANTIAL AMENDMENT
NOTICE OF SUBSTANTIAL AMENDMENT For use in the case of all research other than clinical trials of investigational medicinal products (CTIMPs). For substantial amendments to CTIMPs, please use the EU-approved
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationABNORMALITIES IN LUNG FUNCTION AMONG MULTIPLY- TRANSFUSED THALASSEMIA PATIENTS: RESULTS FROM A THALASSEMIA CENTER IN MALAYSIA
ABNORMALITIES IN LUNG FUNCTION AMONG MULTIPLY- TRANSFUSED THALASSEMIA PATIENTS: RESULTS FROM A THALASSEMIA CENTER IN MALAYSIA R Jamal 1, J Baizura 1, A Hamidah 1, N Idris 2, AH Jeffrey 3 and H Roslan 3
More informationSpirometry is the most frequently performed. Obstructive and restrictive spirometric patterns: fixed cut-offs for FEV1/FEV6 and FEV6
Eur Respir J 2006; 27: 378 383 DOI: 10.1183/09031936.06.00036005 CopyrightßERS Journals Ltd 2006 Obstructive and restrictive spirometric patterns: fixed cut-offs for FEV1/ and J. Vandevoorde*, S. Verbanck
More informationChapter 24. Kyphoscoliosis. Mosby items and derived items 2011, 2006 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 24 Kyphoscoliosis 1 A Figure 24-1. Kyphoscoliosis. Posterior and lateral curvature of the spine causing lung compression. Excessive bronchial secretions (A) and atelectasis (B) are common secondary
More informationThoracic lung involvement in rheumatoid arthritis: Findings on HRCT
Thoracic lung involvement in rheumatoid arthritis: Findings on HRCT Poster No.: C-2488 Congress: ECR 2015 Type: Educational Exhibit Authors: R. E. Correa Soto, M. J. Martín Sánchez, J. M. Fernandez 1 1
More informationO ccupational asthma (OA) is the most commonly
58 ORIGINAL ARTICLE Changes in rates and severity of compensation claims for asthma due to diisocyanates: a possible effect of medical surveillance measures S M Tarlo, G M Liss, K S Yeung... See end of
More informationLung Pathophysiology & PFTs
Interpretation of Pulmonary Function Tests (PFTs) Course # 1612 2:00 5:00pm Friday February 22, 2013 Lung Pathophysiology & PFTs Mark F. Sands MD, FCCP, FAAAAI Division of Allergy, Immunology & Rheumatology
More informationTeacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology
Title: Spirometry Teacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology I. Measurements of Ventilation Spirometry A. Pulmonary Volumes 1. The tidal
More informationCOPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases
COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose
More informationPulmonary Function Tests. Mohammad Babai M.D Occupational Medicine Specialist
Pulmonary Function Tests Mohammad Babai M.D Occupational Medicine Specialist www.drbabai.com Pulmonary Function Tests Pulmonary Function Tests: Spirometry Peak-Flow metry Bronchoprovocation Tests Body
More informationNew Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis
New Evidence reports on presentations given at EULAR 2011 Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis Report on EULAR 2011 presentations Anti-TNF failure and response to rituximab
More informationFVC to Slow Inspiratory Vital Capacity Ratio* A Potential Marker for Small Airways Obstruction
Original Research PSYCHOLOGICAL TESTING FVC to Slow Inspiratory Vital Capacity Ratio* A Potential Marker for Small Airways Obstruction Judith Cohen, MD; Dirkje S. Postma, MD, PhD; Karin Vink-Klooster;
More informationIs there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions?
Respiratory Medicine (2004) 98, 178 183 Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions? Maria Tsoumakidou, Nikolaos Tzanakis,
More informationCASE OF THE MONTH. Lung Disease in Rheumatoid Arthritis
CASE OF THE MONTH Lung Disease in Rheumatoid Arthritis 61 year old male Maōri Height: 174 cm Weight: 104.6kg BMI: 34.55 Problems 1. Rheumatoid related interstitial lung disease with UIP pattern 2. Secondary
More informationBPCO: dalle novità patogenetiche alla terapia
BPCO: dalle novità patogenetiche alla terapia Gianna Camiciottoli Dip. Di Scienze Biomediche, Sperimentali e Cliniche Mario Serio Università degli Studi di Firenze Firenze, 11 novembre 2016 Conflict of
More informationChapter 3. Pulmonary Function Study Assessments. Mosby items and derived items 2011, 2006 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 3 Pulmonary Function Study Assessments 1 Introduction Pulmonary function studies are used to: Evaluate pulmonary causes of dyspnea Differentiate between obstructive and restrictive pulmonary disorders
More informationexacerbation has greater impact on functional status than frequency of exacerbation episodes.
Original Article Singapore Med J 2011, 52(12) 894 Changes in the BODE index, exacerbation duration and hospitalisation in a cohort of COPD patients Bu X N, Yang T, Thompson M A, Hutchinson A F, Irving
More informationClinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia
Original article: Clinical research SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2013; 30; 103-112 Mattioli 1885 Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia
More informationDOES SMOKING MARIJUANA INCREASE THE RISK OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE?
DOES SMOKING MARIJUANA INCREASE THE RISK OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Pubdate: Tue, 14 Apr 2009 Source: Canadian Medical Association Journal (Canada) Copyright: 2009 Canadian Medical Association
More informationMeenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar
Comparison of Improvement in Quality of Life Score with Objective Parameters of Pulmonary Function in Indian Asthmatic Children Receiving Inhaled Corticosteroid Therapy Meenu Singh, Joseph L. Mathew, Prabhjot
More informationE. Prescott + **, P. Lange* +, J. Vestbo**
Eur Respir J, 1995, 8, 1333 1338 DOI: 10.1183/09031936.95.08081333 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Chronic mucus hypersecretion
More informationMai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012
Mai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012 Recognize the importance of Pulmonary Function Testing in Cystic Fibrosis Be aware of different types
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationSerial pulmonary function tests in progressive systemic sclerosis
Thorax, 1979, 34, 224-228 Serial pulmonary function tests in progressive systemic sclerosis L R BAGG AND D T D HUGHES From the Pulmonary Research Unit, Departnment of Chest Medicine, London Hospital, London,
More informationPULMONARY FUNCTION TESTS
Chapter 4 PULMONARY FUNCTION TESTS M.G.Rajanandh, Department of Pharmacy Practice, SRM College of Pharmacy, SRM University. OBJECTIVES Review basic pulmonary anatomy and physiology. Understand the reasons
More informationR etrospective studies on the natural history of fibrosing
517 EXTENDED REPORT Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis J K Dawson, H E Fewins, J Desmond, M P Lynch, D R Graham... See end of article
More informationRheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)
Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology
More informationCombined pulmonary fibrosis and emphysema; prevalence and follow up among health-care personnel
Combined pulmonary fibrosis and emphysema; prevalence and follow up among health-care personnel Poster No.: C-0698 Congress: ECR 2013 Type: Scientific Exhibit Authors: K. Chae, G. Jin, S. Chon, Y. Lee;
More informationRespiratory Disease. Dr Amal Damrah consultant Neonatologist and Paediatrician
Respiratory Disease Dr Amal Damrah consultant Neonatologist and Paediatrician Signs and Symptoms of Respiratory Diseases Cardinal Symptoms Cough Sputum Hemoptysis Dyspnea Wheezes Chest pain Signs and Symptoms
More informationAssessment of Pulmonary Function Test (Pft) In Patients of Ankylosing Spondylitis
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 8 Ver. X (Aug. 2017), PP 63-68 www.iosrjournals.org Assessment of Pulmonary Function Test (Pft)
More informationIdiopathic pulmonary fibrosis (IPF) is a
Eur Respir J 2011; 38: 176 183 DOI: 10.1183/09031936.00114010 CopyrightßERS 2011 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema S.L. Schmidt*,
More informationKey words: bronchodilation; diffusing capacity; high-resolution CT; lung volumes; spirometry
Assessment of Emphysema in COPD* A Functional and Radiologic Study Isa Cerveri, MD; Roberto Dore, MD; Angelo Corsico, MD, PhD; Maria C. Zoia, MD; Riccardo Pellegrino, MD; Vito Brusasco, MD; and Ernesto
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationTriennial Pulmonary Workshop 2012
Triennial Pulmonary Workshop 2012 Rod Richie, M.D., DBIM Medical Director Texas Life Insurance Company, Waco, TX EMSI, Waco, TX Lisa Papazian, M.D., DBIM Assistant Vice President and Medical Director Sun
More informationAnyone who smokes and/or has shortness of breath and sputum production could have COPD
COPD DIAGNOSIS AND MANAGEMENT CHECKLIST Anyone who smokes and/or has shortness of breath and sputum production could have COPD Confirm Diagnosis Presence and history of symptoms: Shortness of breath Cough
More informationOFEV MEDIA BACKGROUNDER
OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small
More informationRegional lung function in ankylosing
Regional lung function in ankylosing RUSSELL M. STEWART', JOHN B. RIDYARD, and JOHN D. PEARSON Regional Cardio-Thoracic Centre, Broadgreen Hospital, Liverpool L14 3LB Thorax (1976), 31, 433. Stewart, R.
More informationCOPD in Korea. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum
COPD in Korea Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum Mortality Rate 1970-2002, USA JAMA,2005 Global Burden of Disease: COPD WHO & World
More informationJ. van Aken* H. van Dongen* S. le Cessie F.C. Breedveld T.W.J. Huizinga. * both authors contributed equally
CHAPTER Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study J. van Aken* H. van
More informationEvidence Review: Title. Month/ Year. Evidence Review:
Evidence Review: Title Month/ Year Evidence Review: Rituximab for connective tissue disease associated interstitial lung disease October 2014 Standard Operating Procedure: NHS England Evidence Review:
More informationPulmonary manifestations may account for. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis
Eur Respir J 2009; 33: 1053 1061 DOI: 10.1183/09031936.00091608 CopyrightßERS Journals Ltd 2009 Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis G. Devouassoux*, **, V. Cottin
More informationOnline Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey
Online Data Supplement Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey Dong Soon Kim, MD, Young Sam Kim MD, Kee Suk Chung MD, Jung Hyun Chang
More informationPulmonary function tests findings and their diagnostic value in patients with IgG4-related disease
Original Article Pulmonary function tests findings and their diagnostic value in patients with IgG4-related disease Lu Cao, Yi-Bing Chen, Da-Hui Zhao, Wen-Fang Shi, Song Meng, Li-Xin Xie Department of
More informationJosh Stanton and Michael Epton Respiratory Physiology Laboratory, Canterbury Respiratory Research Group Christchurch Hospital
Josh Stanton and Michael Epton Respiratory Physiology Laboratory, Canterbury Respiratory Research Group Christchurch Hospital Setting Scene Advancements in neonatal care over past 30 years has resulted
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationPulmonary Function Testing
Pulmonary Function Testing Let s catch our breath Eddie Needham, MD, FAAFP Program Director Emory Family Medicine Residency Program Learning Objectives The Astute Learner will: Become familiar with indications
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of insertion of endobronchial nitinol coils to improve lung function in emphysema
More informationDetection of alveolar epithelial injury by Tc-99m DTPA radioaerosol inhalation lung scan in rheumatoid arthritis patients
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 19, No. 6, 455 460, 2005 Detection of alveolar epithelial injury by Tc-99m DTPA radioaerosol inhalation lung scan in rheumatoid arthritis patients Berna
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationRESPIRATORY PHYSIOLOGY Pre-Lab Guide
RESPIRATORY PHYSIOLOGY Pre-Lab Guide NOTE: A very useful Study Guide! This Pre-lab guide takes you through the important concepts that where discussed in the lab videos. There will be some conceptual questions
More informationnormal and asthmatic males
Lung volume and its subdivisions in normal and asthmatic males MARGARET I. BLACKHALL and R. S. JONES1 Thorax (1973), 28, 89. Institute of Child Health, University of Liverpool, Alder Hey Children's Hospital,
More informationBronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh
Bronchiectasis Domiciliary treatment Prof. Adam Hill Royal Infirmary and University of Edinburgh Plan of talk Background of bronchiectasis Who requires IV antibiotics Domiciliary treatment Results to date.
More informationORIGINAL INVESTIGATION. Progressive Preclinical Interstitial Lung Disease in Rheumatoid Arthritis
ORIGINAL INVESTIGATION Progressive Preclinical Interstitial Lung Disease in Rheumatoid Arthritis Bernadette R. Gochuico, MD; Nilo A. Avila, MD; Catherine K. Chow, MD; Levi J. Novero, MD; Hai-Ping Wu, BS;
More informationPROGNOSTIC VALUE OF QUANTITATIVE MEASUREMENT OF RHEUMATOID FACTOR IN EARLY RHEUMATOID ARTHRITIS
British Journal of Rheumatology 1995;34:1146-1150 PROGNOSTIC VALUE OF QUANTITATIVE MEASUREMENT OF RHEUMATOID FACTOR IN EARLY RHEUMATOID ARTHRITIS L. PAEVDELA, T. PALOSUO,* M. LEIRISALO-REPO,t T. HELVE
More informationThe role of Pulmonary function Testing In Interstitial lung disease in infants. [ ipft in child ]
The role of Pulmonary function Testing In Interstitial lung disease in infants [ ipft in child ] Introduction Managing infants with diffuse lung disease (DLD) suspected to have interstitial lung disease
More informationA comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma
Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires
More informationTHE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G)
British Journal of Rheumatology 1996;35:66-71 THE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G) S. D. JONES, A. STEINER,* S. L. GARRETT and A. CALIN Royal National Hospital for Rheumatic Diseases,
More informationPULMONARY FUNCTION. VOLUMES AND CAPACITIES
PULMONARY FUNCTION. VOLUMES AND CAPACITIES The volume of air a person inhales (inspires) and exhales (expires) can be measured with a spirometer (spiro = breath, meter = to measure). A bell spirometer
More information